Tolerability, Safety, and Pharmacodynamics of Danuglipron for Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes
Diabetes Obes Metab 2023 Jun 13;[EPub Ahead of Print], AR Saxena, JP Frias, DN Gorman, RN Lopez, N Andrawis, N Tsamandouras, MJ BirnbaumFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.